Leah Brownlee is a member of our Corporate Practice Group, where she advises corporate and securities law matters within the life sciences industry and more broadly, in the tech sector, including venture capital and strategic financing, public and private capital markets transactions, securities law compliance, stock exchange listing requirements, strategic intellectual property advice and corporate governance, and international business transactions. She also has expertise in counseling public and private companies in connection with other corporate transactions, including mergers, acquisitions, dispositions and joint ventures, manufacturing, distribution and research agreements, and on general business matters.

    Leah previously worked for the firm, and another global law firm, as an associate in the Corporate Practice Group, where she counseled public and private companies in connection with corporate transactions, including mergers, acquisitions, dispositions and joint ventures, and on general business and securities law matters.

    Prior to returning to our firm in 2016, Leah served in-house for life sciences companies in executive and board level assignments, providing her with a unique perspective on the challenges and opportunities that growing companies in this field face across this global industry.

    She is a Vice Chair of the American Health Lawyers Association's Life Science Practice Group and a Vice Chair of the American Bar Association, Biotechnology Committee. She is also a member of the Food Drug Law Institute and is active in BioOhio.

    Award Mouse thought multimedia interface book medal screen monitor
    • Represented numerous companies and investors in connection with private financing transactions within the life sciences industry.
    • Advised various foreign tech sector companies on their initial entry into the US, including conduct of “Delaware Flip” transactions to prepare companies for US-based investment.
    • Represented NASDAQ-listed biotech company in public, private and debt financings, totaling more than US$100 million and including both US and foreign-based institutional and individual high-net-worth investors.
    • Formed, counseled on investment into, and served as chairman of the board for joint venture company between NASDAQ-listed biotech company and large Russian government venture fund.
    • Advising life science companies on licensing, distribution and other transactions.
    • Served as Executive Vice President, Compliance and Operations, and Corporate Secretary of a NASDAQ-listed clinical-stage biotechnology company with a focus on radiation mitigation and oncology immunotherapy development. Managed applications for more than US$150 million of government contracts from US Department of Defense and the Biomedical Advanced Research and Development Authority of the Department of Health and Human Services – US$60 million was granted.
    • Served as Vice President, Legal and Operations for a discovery-stage biotechnology company. Provided counsel in general corporate and transactional areas primarily related to corporate resolutions, operating agreements, investment documents, founders stock issuance and associated grant documents and shareholder agreements.
    • Served in the Medical Innovations area of Cleveland Clinic, counseling and assisting spin-off companies in various financing and corporate-related matters.


    • Case Western Reserve University, J.D., 2005
    • University of Arkansas, B.S., Chemical Engineering, 2002


    • Illinois, 2008
    • Ohio, 2005

    Memberships and Affiliations

    • Vice Chair, Life Sciences Committee – American Health Lawyers Association
    • American Bar Association, Biotechnology Committee
    • BioOhio
    • Notable Women in Technology, Crain’s Cleveland Business, 2018

    {{insights.date}} {{insights.source}} {{insights.type}}
    Award Mouse thought multimedia interface book medal screen monitor